France
SeaBeLife Biotech, founded in 2019 and headquartered in France, is a promising player in the Biotechnology sector. With its slogan, “Solutions to deprogram cell death: A breakthrough innovation to treat and prevent severe pathologies”, the company emphasizes its innovative approach in developing small molecules that inhibit regulated necrosis, a crucial pathophysiological factor in numerous severe diseases.
The company is strategically focusing on acute and orphan diseases, aiming for expedited proof of concept by tackling conditions such as acute kidney injury (AKI) and acute liver failure (ALF). SeaBeLife Biotech has selected a lead molecule currently undergoing preclinical trials to address these conditions. Additionally, potential molecules for neurodegenerative diseases and AMD have shown promising in cellulo proof of concept.
The company recently secured a €2.00M Pre-Seed investment from investors including Angels Santé, BREIZH Angels, iXLife, and others on 01 October 2025, highlighting strong investor confidence in its groundbreaking therapies.
